1. Search Result
Search Result
Results for "

CD34

" in MedChemExpress (MCE) Product Catalog:

15

Inhibitors & Agonists

1

MCE Kits

3

Inhibitory Antibodies

1

Natural
Products

6

Recombinant Proteins

1

Antibodies

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P990351

    Transmembrane Glycoprotein Inflammation/Immunology
    The Anti-CD34 Antibody is a human-derived antibody expressed in CHO, targeting CD34. The Anti-CD34 Antibody contains huIgG2 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-CD34 Antibody can be referenced from Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-CD34 Antibody
  • HY-106784

    Fungal Apoptosis Infection Cancer
    Ajoene, a garlic-derived compound, is an antithrombotic and antifungal agent. Ajoene inhibits proliferation and induces apoptosis of human leukaemia CD34-negative cells including HL-60, U937, HEL and OCIM-I. Anticancer activities .
    Ajoene
  • HY-110208
    BRD9876
    1 Publications Verification

    Kinesin Microtubule/Tubulin Cancer
    BRD9876 is the “rigor” inhibitor that locks kinesin-5 (Eg5) in a state with enhanced microtubules (MTs) binding, leading to bundling and stabilization of MTs. BRD9876 interacts with the tyrosine 104 residue that is part of the α4-α6 allosteric binding pocket. BRD9876 specifically targets microtubule-bound Eg5 and selectively inhibits myeloma over CD34 cells. BRD9876 has the potential for multiple myeloma (MM) research .
    BRD9876
  • HY-150109A

    HDAC Cancer
    Purinostat is a selective inhibitor of HDAC I/IIb with anti-leukemic activity. Purinostat mesylate (HY-150109), the mesylate salt of Purinostat, inhibits the survival of Ph+ leukemic cells and CD34+ leukemic cells derived from CML patients. Purinostat mesylate targets HDAC I/IIb to inhibit several important factors for leukemic stem cell (LSC) survival, including c-Myc, β-Catenin, E2f, Ezh2, Alox5, and mTOR. Purinostat mesylate increases glutamate metabolism in LSC by increasing GLS1 .
    Purinostat
  • HY-RS02236

    Small Interfering RNA (siRNA) Others

    CD34 Human Pre-designed siRNA Set A contains three designed siRNAs for CD34 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    CD34 Human Pre-designed siRNA Set A
    CD34 Human Pre-designed siRNA Set A
  • HY-P990274

    Transmembrane Glycoprotein Others
    Anti-Canine CD34 Antibody (1H6) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to canine CD34.
    Anti-Canine CD34 Antibody (1H6)
  • HY-15001A

    SR1 hydrochloride

    Aryl Hydrocarbon Receptor Others
    Stemregenin 1 hydrochloride is a purine derivative that antagonizes aryl hydrocarbon receptor signaling in CD34+ cells. IC50 The value is 127 nM. Stemregenin 1 hydrochloride can be used to expand the pluripotency of hematopoietic stem cells (HSC) in stem cell studies .
    Stemregenin 1 hydrochloride
  • HY-150239

    BAY-299N

    DNA/RNA Synthesis Cancer
    BAY-364 (BAY-299N) is an inhibitor of the second bromine domain in TAF1. BAY-364 inhibits the TAF1 of Kasumi-1 cells, CD34 + cells and K562 cells with IC50 values of 1.0 µM, 10.4 µM and 10.0 µM respectively .
    BAY-364
  • HY-125090

    Aurora Kinase c-Myc Bcr-Abl Histone Methyltransferase Apoptosis Cancer
    PHA-680626 is an effective inhibitor of the interaction between Aurora-A and N-Myc. PHA-680626 inhibits kinase activity of AURKA and Bcr-Abl, and induces N-Myc degradation. PHA-680626 decreases phosphorylation of CrkL and histone H3. PHA-680626 shows anti-proliferative and pro-apoptotic activity on Imatinib (HY-15463)-resistant chronic myeloid leukemia cell lines and primary CD34+ cells .
    PHA-680626
  • HY-108417

    STAT JAK Bcr-Abl Cancer
    Debio 0617B, a multi-kinase inhibitor, reduces maintenance and self-renewal of primary human AML CD34 + stem/progenitor cells. Debio 0617B has a unique profile targeting key kinases upstream of STAT3/STAT5 signaling such as JAK, SRC, ABL, and class III/V receptor tyrosine kinases (TKs). Debio 0617B has documented efficacy in STAT3-driven solid tumors .
    Debio 0617B
  • HY-P990352

    Scavenger Receptor Class B type I (SR-BI) Inflammation/Immunology
    Anti-CD36 Antibody is a humanized antibody expressed in CHO that targets CD36. The Anti-CD36 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CD36 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-CD36 Antibody
  • HY-15306
    Eltrombopag
    Maximum Cited Publications
    15 Publications Verification

    SB-497115

    Thrombopoietin Receptor Bacterial Apoptosis Infection Cardiovascular Disease Cancer
    Eltrombopag (SB-497115) is an orally active thrombopoietin receptor nonpeptide agonist. Eltrombopag owns thrombopoietic activity, and has been used to research low blood platelet counts with chronic immune thrombocytopenia. Eltrombopag can be used for the research of cardiovascular. Eltrombopag also has highly inhibitory effects against multidrug resistant Staphylococcus aureus. Eltrombopag can induce apoptosis in hepatocellular carcinomab (HCC) as well .
    Eltrombopag
  • HY-15306R

    Thrombopoietin Receptor Bacterial Apoptosis Infection Cardiovascular Disease Cancer
    Eltrombopag (Standard) is the analytical standard of Eltrombopag. This product is intended for research and analytical applications. Eltrombopag (SB-497115) is an orally active thrombopoietin receptor nonpeptide agonist. Eltrombopag owns thrombopoietic activity, and has been used to research low blood platelet counts with chronic immune thrombocytopenia. Eltrombopag can be used for the research of cardiovascular. Eltrombopag also has highly inhibitory effects against multidrug resistant Staphylococcus aureus. Eltrombopag can induce apoptosis in hepatocellular carcinomab (HCC) as well .
    Eltrombopag (Standard)
  • HY-15306AR

    Thrombopoietin Receptor Bacterial Apoptosis Infection Cardiovascular Disease Cancer
    Eltrombopag (Olamine) (Standard) is the analytical standard of Eltrombopag (Olamine). This product is intended for research and analytical applications. Eltrombopag Olamine (Eltrombopag diethanolamine salt) is an orally active thrombopoietin receptor nonpeptide agonist. Eltrombopag Olamine owns thrombopoietic activity, and has been used to research low blood platelet counts with chronic immune thrombocytopenia. Eltrombopag Olamine can be used for the research of cardiovascular. Eltrombopag Olamine also has highly inhibitory effects against multidrug resistant Staphylococcus aureus. Eltrombopag Olamine can induce apoptosis in hepatocellular carcinomab (HCC) as well .
    Eltrombopag (Olamine) (Standard)
  • HY-15306A
    Eltrombopag Olamine
    Maximum Cited Publications
    15 Publications Verification

    Eltrombopag diethanolamine salt; SB-497115GR

    Thrombopoietin Receptor Bacterial Apoptosis Infection Cardiovascular Disease Cancer
    Eltrombopag Olamine (Eltrombopag diethanolamine salt) is an orally active thrombopoietin receptor nonpeptide agonist. Eltrombopag Olamine owns thrombopoietic activity, and has been used to research low blood platelet counts with chronic immune thrombocytopenia. Eltrombopag Olamine can be used for the research of cardiovascular. Eltrombopag Olamine also has highly inhibitory effects against multidrug resistant Staphylococcus aureus. Eltrombopag Olamine can induce apoptosis in hepatocellular carcinomab (HCC) as well .
    Eltrombopag Olamine

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: